Mode
Text Size
Log in / Sign up

Anemia

Subtypes of Anemia

Sickle Cell Disease 9 Iron Deficiency Anemia 4 Severe aplastic anemia 4 Sickle-Cell Anemia 2 Acute Chest Syndrome 1 Alpha-Thalassemia 1 Anemia in preterm infants 1 Atypical hemolytic uremic syndrome 1 CKD-related anemia 1 Malaria-induced anaemia 1 Paroxysmal nocturnal hemoglobinuria 1 Fanconi Anemia 0 Human Parvovirus B19-Associated Aplastic Crisis 0 Thalassemia 0

34 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Anemia

202 trials tracked for Anemia: 103 in phase 3 or 4 and 38 with published results. The most-cited published study has 2093 citations.

202Trials tracked
103Phase 3 & 4
0Recruiting
38With published results
Phase distribution
Phase 4 18 Phase 3 85 Phase 2 53 Phase 1 9 Other / NA 37
  1. Phase 3 A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia Completed · 2,093 cited
  2. Phase 3 Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease Completed · 238 cited
  3. Phase 3 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) Completed · 237 cited
  4. Phase 3 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Completed · 227 cited
  5. Phase 3 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Completed · 217 cited
  6. Phase 3 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD) Completed · 195 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD) Completed · 195 cited
  2. Phase 3 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis Completed · 172 cited
  3. Phase 3 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. Completed · 132 cited
  4. Phase 3 A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Completed · 111 cited
  5. Phase 3 Age of Blood in Children in Pediatric Intensive Care Units Completed · 105 cited
  6. Phase 3 A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients Completed · 78 cited
  7. Phase 3 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) Completed · 73 cited
  8. Phase 3 A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients. Completed · 72 cited
  9. Phase 3 A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients. Completed · 63 cited
  10. Phase 3 Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia Completed · 61 cited
  11. Phase 3 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) Completed · 49 cited
  12. Phase 3 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Completed · 49 cited
  13. Phase 3 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) Completed · 49 cited
  14. Phase 3 Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) Completed · 49 cited
  15. Phase 3 Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Completed · 46 cited
  16. Phase 4 Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients Completed · 45 cited
  17. Phase 3 A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. Completed · 45 cited
  18. Phase 3 (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy Completed · 45 cited
  19. Phase 4 ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion Completed · 11 cited
  20. Phase 3 A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia Completed · 10 cited
  21. Phase 3 A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia Completed · 8 cited
  22. Phase 3 STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients Completed · 8 cited
  23. Phase 3 A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia Completed · 8 cited
  24. Phase 3 A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. Completed · 8 cited
  25. Phase 3 LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. Completed · 8 cited
  26. Phase 3 A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia Completed · 8 cited
  27. Phase 3 MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia Completed · 8 cited
  28. Phase 3 A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia. Completed · 8 cited
  29. Phase 3 Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients Completed · 7 cited
  30. Phase 3 A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients. Completed · 7 cited
  31. Phase 3 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia Completed · 7 cited
  32. Phase 3 Myocardial Ischemia and Transfusion Completed · 7 cited
  33. Phase 4 A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. Completed
  34. Phase 4 A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy. Completed
  35. Phase 4 A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia Completed
  36. Phase 4 Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed
  37. Phase 4 Predictors of Response to Iron and Erythropoietin Stimulating Agents Completed
  38. Phase 4 Treatment Response in Dialysis Anaemia Completed
  39. Phase 4 IV Iron Safety: Evaluation of Iron Species in Healthy Subjects Completed
  40. Phase 4 Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients Completed
  41. Phase 4 A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis Completed
  42. Phase 4 Safety and Efficacy of Iron Sucrose in Children Completed
  43. Phase 4 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes Completed
  44. Phase 4 A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia Completed

Showing the 50 most-cited and recently-updated of 202 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Anemia

Does taking iron powders for five months help children with malaria-induced anaemia?

Taking iron powders for five months helps children with malaria-induced anaemia by raising haemoglobin levels, but it does not improve growth measurements like height or weight.

Full answer →
Do erythropoiesis-stimulating agents help adults with heart failure and anaemia?

ESAs reduce total heart failure hospitalizations and improve hemoglobin and exercise tolerance, but do not lower first hospitalization or mortality risk.

Full answer →
How common is anemia among pregnant women who participate in the WIC program?

Anemia among pregnant WIC participants increased from 10.1% in 2008 to 11.4% in 2018, with higher rates in Black women and later trimesters.

Full answer →